Cargando…
Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants
The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using microfluidics-based antibody affinity profiling (MAAP), we have characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories of SARS-CoV-2 infection and/or vaccinat...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288251/ https://www.ncbi.nlm.nih.gov/pubmed/35875683 http://dx.doi.org/10.1016/j.isci.2022.104766 |
_version_ | 1784748428720340992 |
---|---|
author | Emmenegger, Marc Fiedler, Sebastian Brugger, Silvio D. Devenish, Sean R.A. Morgunov, Alexey S. Ilsley, Alison Ricci, Francesco Malik, Anisa Y. Scheier, Thomas Batkitar, Leyla Madrigal, Lidia Rossi, Marco Meisl, Georg Lynn, Andrew K. Saleh, Lanja von Eckardstein, Arnold Knowles, Tuomas P.J. Aguzzi, Adriano |
author_facet | Emmenegger, Marc Fiedler, Sebastian Brugger, Silvio D. Devenish, Sean R.A. Morgunov, Alexey S. Ilsley, Alison Ricci, Francesco Malik, Anisa Y. Scheier, Thomas Batkitar, Leyla Madrigal, Lidia Rossi, Marco Meisl, Georg Lynn, Andrew K. Saleh, Lanja von Eckardstein, Arnold Knowles, Tuomas P.J. Aguzzi, Adriano |
author_sort | Emmenegger, Marc |
collection | PubMed |
description | The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using microfluidics-based antibody affinity profiling (MAAP), we have characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories of SARS-CoV-2 infection and/or vaccination. Antibody affinity was similar against the wild-type, delta, and omicron variants (K(A) ranges: 122 ± 155, 159 ± 148, 211 ± 307 μM(-1), respectively), indicating a surprisingly broad and mature cross-clade immune response. Postinfectious and vaccinated subjects showed different IgG profiles, with IgG3 (p-value = 0.002) against spike being more prominent in the former group. Lastly, we found that the ELISA titers correlated linearly with measured concentrations (R = 0.72) but not with affinity (R = 0.29). These findings suggest that the wild-type and delta spike induce a polyclonal immune response capable of binding the omicron spike with similar affinity. Changes in titers were primarily driven by antibody concentration, suggesting that B-cell expansion, rather than affinity maturation, dominated the response after infection or vaccination. |
format | Online Article Text |
id | pubmed-9288251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92882512022-07-18 Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants Emmenegger, Marc Fiedler, Sebastian Brugger, Silvio D. Devenish, Sean R.A. Morgunov, Alexey S. Ilsley, Alison Ricci, Francesco Malik, Anisa Y. Scheier, Thomas Batkitar, Leyla Madrigal, Lidia Rossi, Marco Meisl, Georg Lynn, Andrew K. Saleh, Lanja von Eckardstein, Arnold Knowles, Tuomas P.J. Aguzzi, Adriano iScience Article The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using microfluidics-based antibody affinity profiling (MAAP), we have characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories of SARS-CoV-2 infection and/or vaccination. Antibody affinity was similar against the wild-type, delta, and omicron variants (K(A) ranges: 122 ± 155, 159 ± 148, 211 ± 307 μM(-1), respectively), indicating a surprisingly broad and mature cross-clade immune response. Postinfectious and vaccinated subjects showed different IgG profiles, with IgG3 (p-value = 0.002) against spike being more prominent in the former group. Lastly, we found that the ELISA titers correlated linearly with measured concentrations (R = 0.72) but not with affinity (R = 0.29). These findings suggest that the wild-type and delta spike induce a polyclonal immune response capable of binding the omicron spike with similar affinity. Changes in titers were primarily driven by antibody concentration, suggesting that B-cell expansion, rather than affinity maturation, dominated the response after infection or vaccination. Elsevier 2022-07-16 /pmc/articles/PMC9288251/ /pubmed/35875683 http://dx.doi.org/10.1016/j.isci.2022.104766 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Emmenegger, Marc Fiedler, Sebastian Brugger, Silvio D. Devenish, Sean R.A. Morgunov, Alexey S. Ilsley, Alison Ricci, Francesco Malik, Anisa Y. Scheier, Thomas Batkitar, Leyla Madrigal, Lidia Rossi, Marco Meisl, Georg Lynn, Andrew K. Saleh, Lanja von Eckardstein, Arnold Knowles, Tuomas P.J. Aguzzi, Adriano Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants |
title | Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants |
title_full | Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants |
title_fullStr | Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants |
title_full_unstemmed | Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants |
title_short | Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants |
title_sort | both covid-19 infection and vaccination induce high-affinity cross-clade responses to sars-cov-2 variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288251/ https://www.ncbi.nlm.nih.gov/pubmed/35875683 http://dx.doi.org/10.1016/j.isci.2022.104766 |
work_keys_str_mv | AT emmeneggermarc bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT fiedlersebastian bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT bruggersilviod bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT devenishseanra bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT morgunovalexeys bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT ilsleyalison bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT riccifrancesco bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT malikanisay bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT scheierthomas bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT batkitarleyla bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT madrigallidia bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT rossimarco bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT meislgeorg bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT lynnandrewk bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT salehlanja bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT voneckardsteinarnold bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT knowlestuomaspj bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants AT aguzziadriano bothcovid19infectionandvaccinationinducehighaffinitycrosscladeresponsestosarscov2variants |